Caroline Loew, Mural Oncology CEO

Mur­al On­col­o­gy spins out from Alk­er­mes with $275M and a lead im­munother­a­py pro­gram

Mur­al On­col­o­gy is spin­ning out of Alk­er­mes with $275 mil­lion and a lead im­munother­a­py can­di­date al­ready in two stud­ies in mu­cos­al melanoma and ovar­i­an can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA